A cavernous malformation is a cluster of abnormal blood vessels, usually in the brain or spinal cord, where tightly packed capillaries form a small, berry-like mass. These vessels have thin, leaky walls and no normal brain tissue between them. They affect roughly 0.4% to 0.8% of the general population, making them the second most common vascular finding on brain MRI after aneurysms. Many people live their entire lives without knowing they have one.
What a Cavernous Malformation Looks Like
You may also see these called cavernomas, cavernous angiomas, or CCMs (cerebral cavernous malformations). Whatever the name, the structure is the same: a tangle of tiny blood vessels with walls so thin they slowly leak. Because the vessels are packed together without normal tissue in between, the lesion resembles a small mulberry or raspberry. On imaging, radiologists describe it as having a “popcorn” appearance.
The walls of these blood vessels lack the structural proteins that keep normal capillaries sealed. Blood seeps out slowly and deposits iron-containing compounds (hemosiderin) in the surrounding brain tissue. That iron buildup forms a dark ring around the malformation visible on MRI, and it plays a direct role in causing symptoms. The leaked blood products irritate nearby brain cells, trigger local inflammation, and can create scar tissue in the surrounding area.
Who Gets Them
Cavernous malformations show up in two main age groups: adolescents and middle-aged adults. About 1 in 625 people who have no neurological symptoms at all are walking around with one. There’s no significant difference in how often they occur between men and women, though some evidence suggests the risk of bleeding may be slightly higher in women and younger people.
There are two forms. Sporadic cases, which make up the majority, typically involve a single lesion and arise without a family history. Familial cases are inherited in a pattern where only one copy of a mutated gene is needed. People with the familial form usually develop multiple lesions and tend to have more aggressive disease. Three genes are responsible: CCM1 (the most commonly affected), CCM2, and CCM3. All three produce proteins that help maintain the structural integrity of blood vessel walls. When any one of these genes is disrupted, the vessels lose their ability to form tight seals between cells, leading to the leaky, malformed clusters.
If you have a family member with multiple cavernous malformations, genetic testing can identify whether you carry one of these mutations.
Common Symptoms
The single most common outcome is no symptoms at all. In a large prospective study, 44% of people diagnosed with a cavernous malformation were found incidentally, meaning the lesion showed up on a brain scan done for an unrelated reason.
When symptoms do occur, seizures are the most frequent. About one-third of people with a diagnosed CCM initially present with an epileptic seizure. Most of these seizures happen without any detectable bleed. Instead, they result from hemosiderin irritating the surrounding brain tissue, particularly when the malformation sits in the cortex or temporal lobe. The iron deposits cause inflammation and scarring that make nearby neurons fire abnormally.
Hemorrhage accounts for another subset of presentations. About 13% of people first learn they have a CCM because of a symptomatic bleed. Unlike the catastrophic bleeding that can occur with other vascular problems, CCM hemorrhages tend to be small, slow leaks. But because these lesions often sit in or near critical brain structures, even a small bleed can cause noticeable focal neurological deficits: weakness on one side, vision changes, difficulty with speech, or balance problems depending on the location. Headaches, sometimes resembling migraines, are another common complaint.
How Likely Is Bleeding
The overall annual hemorrhage rate is about 1% per lesion per year. But that number varies significantly depending on history. Cavernous malformations that have already caused symptoms (seizures, headaches, or a prior bleed) carry a hemorrhage rate of 1.5% per year. Those found incidentally and never symptomatic bleed at a much lower rate of just 0.29% per year.
Location matters too. Lesions in the brainstem or deep brain structures and those in younger patients carry higher bleeding risk. Once a CCM has bled, the risk of re-bleeding is elevated for a period before gradually declining.
How They’re Diagnosed
MRI is the gold standard, with nearly 100% sensitivity when the right sequences are used. The classic finding is a mixed-signal core with a “popcorn” pattern surrounded by a dark hemosiderin rim. That dark border creates a “blooming” effect on certain MRI sequences, which is almost unmistakable, though it can make the lesion appear slightly larger than it actually is.
Specialized MRI sequences that are highly sensitive to blood products are essential for detecting smaller or multiple lesions that standard scans might miss. Contrast-enhanced MRI helps distinguish a bleeding cavernous malformation from other possibilities like a hemorrhagic tumor or a spontaneous blood clot. CT scans have a limited role because they lack the specificity to reliably identify these lesions.
Treatment: Observation vs. Surgery
Many cavernous malformations never need treatment. If yours was found incidentally and has never caused symptoms, the standard approach is monitoring with periodic MRI scans. The low annual bleed risk for asymptomatic lesions means the risks of surgery often outweigh the benefits of leaving it alone.
Surgery becomes a more serious consideration when a CCM has caused repeated hemorrhages, progressive neurological symptoms, or seizures that don’t respond well to medication. The goal of surgery is complete removal of the lesion along with the surrounding hemosiderin-stained tissue, since that iron deposit is what drives seizure activity. Location is the key factor in whether surgery is feasible. Lesions near the brain’s surface are generally straightforward to access. Those buried deep in the brainstem or other critical areas present a much harder calculation, because the surgical path itself can cause damage.
For deep-seated lesions that are difficult to reach surgically, focused radiation (stereotactic radiosurgery) is an option. A meta-analysis of 850 patients found that radiation reduced hemorrhage rates substantially, with bleeding dropping to roughly 7% of the pre-treatment rate after two years. The risk of symptomatic radiation injury was about 9%, though permanent injury occurred in only around 3% of patients. This makes radiosurgery a reasonable choice for lesions that keep bleeding but sit in locations where open surgery carries unacceptable risk.
Blood Thinners and CCMs
For years, the standard advice was to avoid blood-thinning medications if you had a cavernous malformation, out of concern that they could increase bleeding. Recent research has challenged that assumption. A large systematic review found that patients on blood thinners actually had a lower rate of intracranial hemorrhage, not a higher one. The odds of bleeding were roughly half those of patients not taking these medications.
This is a surprising finding, and researchers caution that it should be treated as hypothesis-generating rather than a definitive green light. The results may reflect selection bias or other factors not fully accounted for. But for people with CCMs who also have conditions requiring blood thinners (like atrial fibrillation or a history of blood clots), this data suggests the decision is more nuanced than a blanket prohibition.
Pregnancy and Cavernous Malformations
Having a cavernous malformation is not a contraindication to pregnancy. Earlier concerns about hormonal changes increasing bleed risk have not been borne out. More recent evidence shows that bleeding rates during pregnancy are similar to those in non-pregnant women, and pregnancy does not appear to worsen clinical symptoms.
Vaginal delivery is safe for most women with CCMs, and there is no indication to perform a cesarean section solely to reduce hemorrhage risk. Surgery on a cavernous malformation during pregnancy is reserved for cases with rapidly worsening symptoms, and even then it’s typically postponed until after delivery when possible. The postpartum period does warrant closer monitoring, as it appears to carry a somewhat elevated risk of bleeding.